

DAFTAR PUSTAKA

- Ahamed, F., Eppler, N., Jones, E. and Zhang, Y., 2024. Understanding macrophage complexity in metabolic dysfunction-associated steatotic liver disease: transitioning from the M1/M2 paradigm to spatial dynamics. *Livers*, 4, pp.455–478.
- Ahmed, M. and Gaffen, S.L., 2010. IL-17 in obesity and adipogenesis. *Cytokine & Growth Factor Reviews*, 21(6), pp.449–453. <https://doi.org/10.1016/j.cytogfr.2010.10.005>
- Alexopoulou, A. and Karayiannis, P., 2014. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. *World Journal of Gastroenterology*, 20(24), pp.7644–7652. <https://doi.org/10.3748/wjg.v20.i24.7644>
- Alisi, A., Carsetti, R. and Nobili, V., 2011. Pathogen or damage associated molecular patterns during nonalcoholic fatty liver disease development. *Hepatology*, 54(5), pp.1500–1502.
- Alkhoury, N., Morris-Stiff, G., Campbell, C., Lopez, R., Tamimi, T.A.R. and Yerian, L. et al., 2012. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. *Liver International*, 32(2), pp.297–302. <https://doi.org/10.1111/j.1478-3231.2011.02639.x>
- Altıparmak, E., Koklu, S., Yalınkılıç, M., Yuksel, O., Cicek, B. and Kayacetin, E. et al., 2005. Viral and host causes of fatty liver in chronic hepatitis B. *World Journal of Gastroenterology*, 11, pp.3056–3059.
- Amacher, D.E. and Chalasani, N., 2014. Drug-induced hepatic steatosis. *Seminars in Liver Disease*, 34(2), pp.205–214. <https://doi.org/10.1055/s-0034-1375960>
- Amato, M.C. and Giordano, C., 2014. Visceral adiposity index: an indicator of adipose tissue dysfunction. *International Journal of Endocrinology*, 2014, pp.1–7.
- Ando, Y. and Jou, J.H., 2021. Nonalcoholic fatty liver disease and recent guideline updates. *Clinics in Liver Disease*, 17, pp.23–28.
- Baars, T., Gieseler, R.K., Patsalis, P.C. and Canbay, A., 2022. Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease. *Metabolism*, 130, p.155179. <https://doi.org/10.1016/j.metabol.2022.155179>
- Babuta, M., Morel, C., de Carvalho Ribeiro, M., Calenda, C., Ortega-Ribera, M. and Nagesh, P.T. et al., 2024. Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis. *Gut*, 73(11), pp.1854–1869.
- Baclig, M.O., Reyes, K.G., Liles, V.R., Mapua, C.A., Dimamay, M.P.S. and Gopez-Cervantes, J., 2018. Hepatic steatosis in chronic hepatitis B: a study of metabolic and genetic factors. *International Journal of Molecular Epidemiology and Genetics*, 9(2), pp.13–19.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI, 2013. *Riset Kesehatan Dasar 2013*. Jakarta: Kementerian Kesehatan RI.

- Basil, B., Myke-Mbata, B.K., Eze, O.E. and Akubue, A.U., 2024. From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions. *Clinical Diabetes and Endocrinology*, 10(1), p.39.
- Bende, R., Heredea, D., Ratiu, I., Sporea, I., Danila, M., Sirlu, R., Popescu, A. and Bende, F., 2025. Association between visceral adiposity and the prediction of hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). *Journal of Clinical Medicine*, 14(10), p.3405. <https://doi.org/10.3390/jcm14103405>
- Beran, A., Ayesh, H., Mhanna, M., Wahood, W., Ghazaleh, S., Abuhelwa, Z., Sayeh, W., Aladamat, N., Musallam, R., Matar, R., Malhas, S.E. and Assaly, R., 2022. Triglyceride-glucose index for early prediction of nonalcoholic fatty liver disease: a meta-analysis of 121,975 individuals. *Journal of Clinical Medicine*, 11(9), p.2666. <https://doi.org/10.3390/jcm11092666>
- Bermúdez, V.J., Salazar, J., Añez, R., Rivas-Ríos, J.R., Chávez-Castillo, M., Torres, W., Núñez, V., Mejías, J., Wilches-Durán, S., Cerda, M., Graterol, M., Graterol, R., Hernández, J., Garicano, C. and Rojas, J., 2017. Optimal cutoff for visceral adiposity index in a Venezuelan population: results from the Maracaibo City Metabolic Syndrome Prevalence Study. *Revista Argentina de Endocrinología y Metabolismo*, 5(4), pp.176–183. <https://doi.org/10.1016/j.raem.2017.07.004>
- Bilzer, M., Roggel, F. and Gerbes, A.L., 2006. Role of Kupffer cells in host defense and liver disease. *Liver International*, 26(10), pp.1175–1186. <https://doi.org/10.1111/j.1478-3231.2006.01342.x>
- Bou Matar, D., Zhra, M., Nassar, W.K., Altemyatt, H., Naureen, A., Abotouk, N., Elahi, M.A. and Aljada, A., 2025. Adipose tissue dysfunction disrupts metabolic homeostasis: mechanisms linking fat dysregulation to disease. *Frontiers in Endocrinology*, 16, p.1592683. <https://doi.org/10.3389/fendo.2025.1592683>
- Browning, J.D. and Horton, J.D., 2004. Molecular mediators of hepatic steatosis and liver injury. *Journal of Clinical Investigation*, 114(2), pp.147–152. <https://doi.org/10.1172/JCI22422>
- Brun, P., Castagliuolo, I., Di Leo, V., Buda, A., Pinzani, M. and Palù, G. et al., 2007. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 292(2), pp.G518–G525. <https://doi.org/10.1152/ajpgi.00024.2006>
- Chait, A. and Den Hartigh, L.J., 2020. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. *Frontiers in Cardiovascular Medicine*, 7, p.22.
- Chalasan, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M. and Cusi, K. et al., 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*, 55(6), pp.2005–2023. <https://doi.org/10.1002/hep.25762>

- Chan, H.L. and Sung, J.J., 2006. Hepatocellular carcinoma and hepatitis B virus. *Seminars in Liver Disease*, 26, pp.153–161.
- Chen H, et al., 2021. Hepatocyte endoplasmic reticulum stress inhibits hepatitis B virus secretion and antiviral efficacy of entecavir. *Front Med*. 8:589040.
- Chen, G., Liang, G., Ou, J., Goldstein, J.L. and Brown, M.S., 2004. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. *Proceedings of the National Academy of Sciences U.S.A.*, 101(31), pp.11245–11250. <https://doi.org/10.1073/pnas.0404297101>
- Chen, Q., Hu, P., Hou, X., Sun, Y., Jiao, M., Peng, L., Dai, Z., Yin, X., Liu, R., Li, Y. et al., 2024. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease. *Cardiovascular Diabetology*, 23, p.232.
- Chen, X.L. and Han, Y.D., 2018. Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients. *European Review for Medical and Pharmacological Sciences*, 22, pp.5640–5646.
- Cheung, A. and Ahmed, A., 2021. Nonalcoholic fatty liver disease and chronic kidney disease: a review of links and risks. *Clinical and Experimental Gastroenterology*, 14, pp.457–465. <https://doi.org/10.2147/CEG.S226130>
- Coste, S.C., Orasan, O.H., Cozma, A., Negrean, V., Sitar-Taut, A.V. and Filip, G.A. et al., 2024. Metabolic dysfunction-associated steatotic liver disease: the associations between inflammatory markers, TLR4, and cytokines IL-17A/F, and their connections to the degree of steatosis and the risk of fibrosis. *Biomedicines*, 12, p.2144.
- Cozma, A., Sitar-Taut, A., Urian, L., Fodor, A. and Suharoschi, R., 2018. Unhealthy lifestyle and the risk of metabolic syndrome—the Romanian experience. *Journal of Mind and Medical Sciences*, 5(2), pp.218–229. <https://doi.org/10.22543/7674.52.P218229>
- Dalekos, G.N., Gatselis, N.K., Zachou, K. and Koukoulis, G.K., 2020. NAFLD and autoimmune hepatitis: do not judge a book by its cover. *European Journal of Internal Medicine*, 76, pp.54–61. <https://doi.org/10.1016/j.ejim.2020.02.001>
- de Almeida Pondé, R.A., 2020. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: a clinical-laboratory approach. *Molecular Biology Reports*, 48, pp.843–854. <https://doi.org/10.1007/s11033-020-06056-4>
- Diao Y, et al. Metabolic Syndrome, Nonalcoholic Fatty Liver Disease, and Chronic Hepatitis B: An Update. *Int J Mol Sci*. 2022. (Cek tahun publikasi yang tepat dari PMC9868033)
- Dietrich, P. and Hellerbrand, C., 2014. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. *Best Practice & Research Clinical Gastroenterology*, 28, pp.637–653.

- Dogan Z, Filik L, Ergül B, Sarıkaya M. Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis. *Saudi J Gastroenterol.* 2015;21(6):396-399.
- Du, W.J., Zhen, J.H., Zeng, Z.Q., Zheng, Z.M., Xu, Y., Qin, L.Y. and Chen, S.J., 2013. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. *Diagnostic Pathology*, 8, p.40. <https://doi.org/10.1186/1746-1596-8-40>
- Erion, D.M., Ignatova, I.D., Yonemitsu, S., Nagai, Y., Chatterjee, P., Weismann, D. et al., 2009. Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of camp response element-binding protein. *Cell Metabolism*, 10(6), pp.499–506.
- Eslam, M., Sanyal, A.J. and George, J., 2020. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology*, 158(7), pp.1999–2014. <https://doi.org/10.1053/j.gastro.2019.11.312>
- European Association for the Study of the Liver, 2021. Clinical practice guidelines on hepatitis B virus infection. *Journal of Hepatology*, 75, pp.1–24.
- Fa, P., Ke, B.G., Dupre, A., Tsung, A. and Zhang, H., 2023. The implication of neutrophil extracellular traps in nonalcoholic fatty liver disease. *Frontiers in Immunology*, 14, p.1292679.
- Farrell, G.C. and Larter, C.Z., 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. *Hepatology*, 43(S1), pp.S99–S112. <https://doi.org/10.1002/hep.20973>
- Fattovich, G., Bortolotti, F. and Donato, F., 2008. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *Journal of Hepatology*, 48(2), pp.335–352. <https://doi.org/10.1016/j.jhep.2007.11.011>
- Ferré, P. and Foufelle, F., 2010. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. *Diabetes, Obesity and Metabolism*, 12(S2), pp.83–92. <https://doi.org/10.1111/j.1463-1326.2010.01275.x>
- Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. and Sanyal, A.J., 2018. Mechanisms of NAFLD development and therapeutic strategies. *Nature Medicine*, 24, pp.908–922. <https://doi.org/10.1038/s41591-018-0104-9>
- Fung, J., Lai, C.L., Seto, W.K. and Yuen, M.F., 2011. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. *Journal of Antimicrobial Chemotherapy*, 66(12), pp.2715–2725. <https://doi.org/10.1093/jac/dkr388>
- Gaffen, S.L., 2009. Structure and signalling in the IL-17 receptor family. *Nature Reviews Immunology*, 9(8), pp.556–567. <https://doi.org/10.1038/nri2586>
- Godfrey, D.I., Hammond, K.J., Poulton, L.D., Smyth, M.J. and Baxter, A.G., 2000. NKT cells: facts, functions and fallacies. *Immunology Today*, 21(11), pp.573–583.
- Guo, J. and Friedman, S.L., 2010. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. *Fibrogenesis & Tissue Repair*, 3, p.21. <https://doi.org/10.1186/1755-1536-3-21>

- Hammerich, L., Heymann, F. and Tacke, F., 2011. Role of IL-17 and Th17 cells in liver diseases. *Clinical and Developmental Immunology*, 2011, p.345803. <https://doi.org/10.1155/2011/345803>
- Henning, J.R., Graffeo, C.S., Rehman, A., Fallon, N.C., Zambirinis, C.P., Ochi, A. et al., 2013. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. *Hepatology*, 58(2), pp.589–602. <https://doi.org/10.1002/hep.26267>
- Hu D, Wang H, Wang H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. *Hepatol Int*. 2018;12(5):438-446.
- Huang Y, et al. Endoplasmic reticulum stress in hepatitis B virus and hepatitis C virus infection. *Front Med*. 2022;9:1051402.
- Huang, Q., Tan, X., Wu, Q., Zhao, H., Chen, H., Yu, X., Wang, J., Huang, X., Huang, Y., Wei, J. et al., 2024. Lipid accumulation product is a valid predictor of hepatic steatosis and nonalcoholic fatty liver disease. *Biomarkers in Medicine*, 18, pp.123–135.
- Huang, S.C. and Liu, C.J., 2023. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives. *Clinical and Molecular Hepatology*, 29(2), pp.320–331. <https://doi.org/10.3350/cmh.2022.0422>
- Iannacone, M. and Guidotti, L.G., 2022. Immunobiology and pathogenesis of hepatitis B virus infection. *Nature Reviews Immunology*, 22, pp.19–32. <https://doi.org/10.1038/s41577-021-00549-4>
- Idilman, I.S., Ozdeniz, I. and Karcaaltincaba, M., 2016. Hepatic steatosis: etiology, patterns, and quantification. *Seminars in Ultrasound, CT and MRI*, 37(6), pp.501–510. <https://doi.org/10.1053/j.sult.2016.08.003>
- Ismail, A., Jaaouani, A., Leucuta, D.C., Popa, S.L. and Dumitrascu, D.L., 2021. The visceral adiposity index in non-alcoholic fatty liver disease and liver fibrosis—systematic review and meta-analysis. *Biomedicine*, 9(12), p.1890. <https://doi.org/10.3390/biomedicine9121890>
- Jiang, D., Chen, C., Liu, X., Huang, C., Yan, D., Zhang, X., Zhou, Y., Lin, Y., Zhou, Y., Guan, Z., Ding, C., Lan, L., Zhu, C., Wu, J., Li, L. and Yang, S., 2021. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. *Annals of Translational Medicine*, 9(23), p.1718. <https://doi.org/10.21037/atm-21-3052>
- Karaman A, Gürsoy S, Soyuer I, et al. Effect of hepatic steatosis on virological response to nucleos(t)ide analogs therapy in patients with chronic hepatitis B. *Turkish J Med Sci*. 2013;43:70-74.
- Kawai, T. and Akira, S., 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nature Immunology*, 11(5), pp.373–384. <https://doi.org/10.1038/ni.1863>
- Khan, R.S., Bril, F., Cusi, K. and Newsome, P.N., 2019. Modulation of insulin resistance in nonalcoholic fatty liver disease. *Hepatology*, 70(2), pp.711–724.
- Kim K.H, Shin H.J, Kim K, Choi H.M, Rhee S.H, Moon H.B, et al. 2007. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of

- SREBP1 and PPAR γ . *Gastroenterology*. 132(5):1955-1967. doi: 10.1053/j.gastro.2007.03.039.
- Kim, D., Chung, G.E., Kwak, M.S., Seo, H.B., Kang, J.H., Kim, W. et al., 2016. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*, 14(1), pp.132–138.
- Kim, J.A., Hwang, S.Y., Yu, J.H., Roh, E., Hong, S.H., Lee, Y.B. et al., 2021. Association of the triglyceride and glucose index with low muscle mass: knhanes 2008-2011. *Scientific Reports*, 11(1), p.450.
- Kim, J.Y., Song, E.H., Lee, H.J., Oh, Y.K., Choi, K.H., Yu, D.Y. et al., 2010. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF- κ B-dependent pathways. *Journal of Molecular Biology*, 397, pp.917–931.
- Kouli, G.M., Panagiotakos, D.B., Kyrou, I., Georgousopoulou, E.N., Chrysohoou, C., Tsigos, C. et al., 2017. Visceral adiposity index and 10-year cardiovascular disease incidence: the ATTICA Study. *Nutrition, Metabolism and Cardiovascular Diseases*, 27(10), pp.881–889.
- Kubes, P. and Mehal, W.Z., 2012. Sterile inflammation in the liver. *Gastroenterology*, 143(5), pp.1158–1172.
- Kumashiro, N., Erion, D.M., Zhang, D., Kahn, M., Beddow, S.A., Chu, X. et al., 2011. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. *Proceedings of the National Academy of Sciences U.S.A.*, 108(39), pp.16381–16385. <https://doi.org/10.1073/pnas.1113359108>
- Kurniawan, L.B., 2024. Triglyceride-glucose index as a biomarker of insulin resistance, diabetes mellitus, metabolic syndrome, and cardiovascular disease: a review. *EJIFCC*, 35(1), pp.44–51.
- Kurniawati, F., Mudjanarko, S.W., Soelistijo, S.A. and Sugihartono, T., 2024. Association of triglyceride and glucose index with non-alcoholic fatty liver disease in type 2 diabetes mellitus patients. *Pharmacognosy Journal*, 16(5), pp.1077–1080. <https://doi.org/10.5530/pj.2024.16.174>
- Lesmana, L.A., Lesmana, C.R.A., Pakasi, L.S. and Krisnuhoni, E., 2012. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. *Acta Medica Indonesiana*, 44(1), pp.35–39.
- Li H, Zhu W, Zhang L, Lei H, Wu X, Guo L, et al. 2015. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. *Sci Rep*. 5:8421. doi: 10.1038/srep08421.
- Li, H., Zhang, Y., Luo, H. and Lin, R., 2022. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults. *Frontiers in Endocrinology*, 13, p.977625.
- Li, N., Li, X., Ding, Y., Liu, X., Diggle, K., Kisseleva, T. and Brenner, D.A., 2023. SREBP regulation of lipid metabolism in liver disease, and therapeutic strategies. *Biomedicines*, 11(12), p.3280. <https://doi.org/10.3390/biomedicines11123280>
- Liaw, Y.F. and Chu, C.M., 2009. Hepatitis B virus infection. *The Lancet*, 373, pp.582–592.

- Liu, X.C., He, G.D., Lo, K., Huang, Y.Q. and Feng, Y.Q., 2021. The triglyceride-glucose index, an insulin resistance marker, was non-linearly associated with all-cause and cardiovascular mortality in the general population. *Frontiers in Cardiovascular Medicine*, 7, p.628109. <https://doi.org/10.3389/fcvm.2020.628109>
- Lukacs-Kornek, V., Hendrikx, T. and Sutti, S., 2024. Inflammatory responses on the road from NASH to HCC: pathogenic mechanisms and possible therapeutic strategies. *Frontiers in Immunology*, 15, p.1512363.
- Machado, M.V., Oliveira, A.G. and Cortez-Pinto, H., 2011. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. *Journal of Gastroenterology and Hepatology*, 26, pp.1361–1367. <https://doi.org/10.1111/j.1440-1746.2011.06801.x>
- Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R. et al., 2003. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology*, 37, pp.917–923.
- McMahon, B.J., 2010. Natural history of chronic hepatitis B. *Clinics in Liver Disease*, 14(3), pp.381–396. <https://doi.org/10.1016/j.cld.2010.05.007>
- Meek, S.E., Nair, K.S. and Jensen, M.D., 1999. Insulin regulation of regional free fatty acid metabolism. *Diabetes*, 48(1), pp.10–14. <https://doi.org/10.2337/diabetes.48.1.10>
- Meyer, M., Schwarzler, J., Jukic, A. and Tilg, H., 2024. Innate immunity and MASLD. *Biomolecules*, 14, p.476.
- Min, Y., Wei, X., Wei, Z., Song, G., Zhao, X. and Lei, Y., 2024. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease. *Cardiovascular Diabetology*, 23, p.188.
- Minakari, M., Molaei, M., Shalmani, H.M., Mohammad Alizadeh, A.H., Jazi, A.H., Naderi, N. et al., 2009. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. *European Journal of Gastroenterology & Hepatology*, 21(5), pp.512–516. <https://doi.org/10.1097/MEG.0b013e328326792e>
- Moon, Y.A., 2017. The SCAP/SREBP pathway: a mediator of hepatic steatosis. *Endocrinology and Metabolism*, 32(1), pp.6–10. <https://doi.org/10.3803/EnM.2017.32.1.6>
- Moslehi, A. and Hamidi-Zad, Z., 2018. Role of SREBPs in liver diseases: a mini-review. *Journal of Clinical and Translational Hepatology*, 6(3), pp.332–338. <https://doi.org/10.14218/JCTH.2017.00061>
- Mulyanto, Depamede, S.N., Surayah, K., Lestarini, I.A., Budianto, W., Hafiludin, Umi, K., Tsuda, F., Takahashi, M. and Okamoto, H., 2008. Hepatitis B virus infection in Eastern part of Indonesia. In: *Abstract book of the second China–Indonesia joint international symposium on hepatobiliary medicine and surgery*. Chongqing, China.
- Mulyanto, Sulaiman, Depamede, N., Surayah, K., Tsuda, F., Ichiyama, K. et al., 2009. A nationwide molecular epidemiological study on hepatitis B virus in

- Indonesia: identification of two novel subgenotypes, B8 and C7. *Archives of Virology*, 154(7), pp.1047–1059.
- Myint, M., Oppedisano, F., De Giorgi, V., Kim, B.M., Marincola, F.M., Alter, H.J. and Nesci, S., 2023. Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions. *Journal of Translational Medicine*, 21(1), p.757. <https://doi.org/10.1186/s12967-023-04627-0>
- Nguyen MH, et al. 2023. Effect modification of hepatitis B viral load on the association between metabolic risk factors and hepatic steatosis. *Transl Gastroenterol Hepatol*. 8:7.
- Ni, W., Shi, J. and Li, J., 2024. Epidemiology, natural history, and management of patients with CHB concurrent with MASLD. *Clinical Liver Disease*, 23, p.e0171. <https://doi.org/10.1097/CLD.0000000000000171>
- Nijhuis, J., Rensen, S.S., Slaats, Y., van Dielen, F.M.H., Buurman, W.A. and Greve, J.W.M., 2009. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. *Obesity*, 17(11), pp.2014–2018. <https://doi.org/10.1038/oby.2009.113>
- O'Shea, J.J., Ma, A. and Lipsky, P., 2002. Cytokines and autoimmunity. *Nature Reviews Immunology*, 2(1), pp.37–45. <https://doi.org/10.1038/nri702>
- Ozercan, A.M. and Ozkan, H., 2022. Vibration-controlled transient elastography in NAFLD: review study. *Euroasian Journal of Hepato-Gastroenterology*, 12(S1), pp.S41–S45. <https://doi.org/10.5005/jp-journals-10018-1365>
- Park, S.J., Garcia Diaz, J., Um, E. and Hahn, Y.S., 2023. Major roles of Kupffer cells and macrophages in NAFLD development. *Frontiers in Endocrinology*, 14, p.1150118.
- Parola, M. and Pinzani, M., 2024. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies. *Molecular Aspects of Medicine*, 95, p.101231. <https://doi.org/10.1016/j.mam.2023.101231>
- Patel, K., Asrani, S.K., Fiel, M.I., Levine, D., Leung, D.H., Duarte-Rojo, A., Dranoff, J.A., Nayfeh, T., Hasan, B. and Taddei, T.H. et al., 2025. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline. *Hepatology*, 81, pp.358–379.
- Pouwels, S., Sakran, N., Graham, Y., Kwantes, I., Tsochatzis, E. and Sharples, A.P. et al., 2022. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. *BMC Endocrine Disorders*, 22(1), p.63. <https://doi.org/10.1186/s12902-022-00980-1>
- Qu, J., Wang, L., Li, Y. and Li, X., 2024. Liver sinusoidal endothelial cell: an important yet often overlooked player in liver fibrosis. *Clinical and Molecular Hepatology*, 30, pp.303–325.
- Ren G, Jia K, Yin S, et al. 2025. Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study. *Virol J*. 22:30. doi: 10.1186/s12985-025-02642-9.

- Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F. et al., 2023. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology*, 78(6), pp.1966–1986. <https://doi.org/10.1097/HEP.0000000000000520>
- Rivera, C.A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M. and Wallace, M., 2007. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. *Journal of Hepatology*, 47(4), pp.571–579.
- Roade, L., Riveiro-Barciela, M., Esteban, R. and Buti, M., 2021. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. *Therapeutic Advances in Infectious Disease*, 8, p.2049936120985954. <https://doi.org/10.1177/2049936120985954>
- Sabio, G., Cavanagh-Kyros, J., Ko, H.J., Jung, D.Y., Gray, S., Jun, J.Y. et al., 2009. Prevention of steatosis by hepatic jnk1. *Cell Metabolism*, 10(6), pp.491–498.
- Seremet, O.C., Oлару, O.T., Ilie, M., Gutu, C.M., Nitulescu, M.G., Diaconu, C. et al., 2018. Determination of pyrrolizidine alkaloids in dietary sources using a spectrophotometric method. *Journal of Mind and Medical Sciences*, 5(2), pp.294–299. <https://doi.org/10.22543/7674.52.P294299>
- Shaikh, S.S., Nafay, S., Reshamwala, S.J., Zaheer, S. and Sajid, M., 2024. Assessment of liver fibrosis grading with non-invasive scoring systems among non-alcoholic fatty liver disease (NAFLD) patients. *Annals of KEMU*, 30(1), pp.37–44.
- Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Fan JG. 2014. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. *World J Gastroenterol*. 20(16):4702-11. doi: 10.3748/wjg.v20.i16.4702. PMID: 24782622; PMCID: PMC4000506.
- Shi MY, Wong C, Lee TP. 2023. Effect modification of hepatitis B viral load on the association between metabolic risk factors and hepatic steatosis. *Transl Gastroenterol Hepatol*. 8:6. doi: 10.21037/tgh-22-44.
- Shi, Y.W., Yang, R.X. and Fan, J.G., 2021. Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion. *World Journal of Gastroenterology*, 27(26), pp.3971–3983.
- Simental-Mendía, L.E., Simental-Mendía, E., Rodríguez-Hernández, H., Rodríguez-Morán, M. and Guerrero-Romero, F., 2016. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women. *Annals of Hepatology*, 15(5), pp.715–720.
- Smith, G.I., Shankaran, M., Yoshino, M., Schweitzer, G.G., Chondronikola, M., Beals, J.W. et al., 2020. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. *Journal of Clinical Investigation*, 130(3), pp.1453–1460.
- Söderberg, C., Marmur, J., Eckes, K., Glaumann, H., Sällberg, M., Frelin, L. et al., 2011. Microvesicular fat, intercellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with

- non-alcoholic steatohepatitis. *APMIS*, 119(7), pp.412–420. <https://doi.org/10.1111/j.1600-0463.2011.02746.x>
- Soemohardjo, S. and Gunawan, S., 2014. Hepatitis B kronik. In: *Buku Ajar Ilmu Penyakit Dalam*. Edisi ke-6, Jilid 1. Jakarta: Interna Publishing, pp.1963–1970.
- Tang, Y., Bian, Z., Zhao, L., Liu, Y., Liang, S., Wang, Q. et al., 2011. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. *Clinical and Experimental Immunology*, 166(2), pp.281–290. <https://doi.org/10.1111/j.1365-2249.2011.04471.x>
- Thomopoulos, K.C., Arvaniti, V., Tsamantas, A.C., Dimitropoulou, D., Gogos, C.A., Siagris, D. et al., 2006. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. *European Journal of Gastroenterology & Hepatology*, 18, pp.233–237.
- Tian, X., Ding, N., Su, Y. and Qin, J., 2023. Comparison of obesity-related indicators for nonalcoholic fatty liver disease diagnosed by transient elastography. *Turkish Journal of Gastroenterology*, 34(10), pp.1078–1087.
- Tilg, H. and Moschen, A.R., 2010. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology*, 52(5), pp.1836–1846. <https://doi.org/10.1002/hep.24001>
- Tomah, S., Salah, T., Al-Badri, M., Dhaver, S., Gardner, H., Tasabehji, M.W. and Hamdy, O., 2023. Multidisciplinary intensive lifestyle intervention improves markers of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes and obesity: a retrospective matched-cohort study. *Clinical Diabetes and Endocrinology*, 9, p.3.
- Tong, S. and Revill, P., 2016. Overview of hepatitis B viral replication and genetic variability. *Journal of Hepatology*, 64(1 Suppl), pp.S4–S16. <https://doi.org/10.1016/j.jhep.2016.01.027>
- Tourkochristou, E., Assimakopoulos, S.F., Thomopoulos, K., Marangos, M. and Triantos, C., 2022. NAFLD and HBV interplay-related mechanisms underlying liver disease progression. *Frontiers in Immunology*, 13, p.965548.
- Tsomidis, I., Voumvouraki, A. and Kouroumalis, E., 2025. Immune checkpoints and the immunology of liver fibrosis. *Livers*, 5, p.5.
- Tudoran, C., Bende, R., Bende, F., Giorgi-Oncu, C., Enache, A., Dumache, R. and Tudoran, M., 2023. Connections between diabetes mellitus and metabolic syndrome and the outcome of cardiac dysfunctions diagnosed during the recovery from COVID-19 in patients without a previous history of cardiovascular diseases. *Biology*, 12, p.370.
- Tumova, J., Andel, M. and Trnka, J., 2016. Excess of free fatty acids as a cause of metabolic dysfunction in skeletal muscle. *Physiological Research*, 65(2), pp.193–207. <https://doi.org/10.33549/physiolres.932993>
- Wang CY, Lu W, Hu DS, Wang GD, Cheng XJ. 2014. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. *World J Gastroenterol*. 20(30):10585-90. doi: 10.3748/wjg.v20.i30.10585. PMID: 25132779; PMCID: PMC4130870.

- Wang X, et al. 2021. Hepatitis B virus infection is not associated with fatty liver disease: evidence from a cross-sectional study in China. *BMC Gastroenterol.* 21:452.
- Wang, H., Tsung, A., Mishra, L. and Huang, H., 2024. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma. *EBioMedicine*, 101, p.105031.
- Wang, J., Yan, S., Cui, Y., Chen, F., Piao, M. and Cui, W., 2022. The diagnostic and prognostic value of the triglyceride-glucose index in metabolic dysfunction-associated fatty liver disease (MAFLD): a systematic review and meta-analysis. *Nutrients*, 14, p.4969.
- Wang, M., Chang, M., Shen, P., Wei, W., Li, H. and Shen, G., 2023. Application value of triglyceride-glucose index and triglyceride-glucose body mass index in evaluating the degree of hepatic steatosis in non-alcoholic fatty liver disease. *Lipids in Health and Disease*, 22, p.186. <https://doi.org/10.1186/s12944-023-01954-5>
- Watt, M.J., Miotto, P.M., De Nardo, W. and Montgomery, M.K., 2019. The liver as an endocrine organ-linking nafld and insulin resistance. *Endocrine Reviews*, 40(5), pp.1367–1393.
- Wong, G.L., Wong, V.W., Choi, P.C., Chan, A.W., Chim, A.M., Yiu, K.K. et al., 2009. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. *Gut*, 58, pp.111–117.
- Wong, V.W., Wong, G.L., Chu, W.C., Chim, A.M., Ong, A., Yeung, D.K. et al., 2012. Hepatitis B virus infection and fatty liver in the general population. *Journal of Hepatology*, 56(3), pp.533–540.
- World Health Organization, 2008. *WHO STEPwise approach to surveillance (STEPS)*. Geneva: World Health Organization.
- Wu YL, Wang D, Peng XE, Chen YL, Zheng DL, Chen WN, et al. 2016. Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. *J Virol.* 90(4):1729-1740. doi: 10.1128/JVI.02604-15.
- Xie, Q.X., Xu, N., Jiang, X.P., Zhang, Y.F., Zhang, Z.H., Li, J.B. et al., 2016. Role of FibroScan in liver fibrosis evaluation in patients with chronic hepatitis B virus infection and related influencing factors. *Zhonghua Gan Zang Bing Za Zhi*, 24, pp.659–664.
- Xu L, Li P, Lu W, Shi Q, Shi R, Zhang X, Liu Y, Wang Q, Fan J, Mi Y. 2016. Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan]. *Zhonghua Gan Zang Bing Za Zhi.* ;24(2):108-13. Chinese. doi: 10.3760/cma.j.issn.1007-3418.2016.02.007. PMID: 26983477.
- Xu, J., Li, Y., Feng, Z. and Chen, H., 2025. Cigarette smoke contributes to the progression of MASLD: from the molecular mechanisms to therapy. *Cells*, 14(3), p.221. <https://doi.org/10.3390/cells14030221>
- Xue, Y., Xu, J., Li, M. and Gao, Y., 2022. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: triglyceride glucose index-related parameters. *Frontiers in Endocrinology*, 13, p.951689.
- Yan, S., Chen, S., Liu, Y., Liang, H., Zhang, X., Zhang, Q. et al., 2023. Associations of serum carotenoids with visceral adiposity index and lipid accumulation

- product: a cross-sectional study based on NHANES 2001–2006. *Lipids in Health and Disease*, 22(1), p.209.
- Yi S, Ren G, Zhu Y, Cong Q. 2024. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study. *Virol J.* 21:22. doi: 10.1186/s12985-023-02277-8.
- Yi, S., Ren, G., Zhu, Y. and Cong, Q., 2024. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study. *Virology Journal*, 21, p.22.
- Younossi, Z., Anstee, Q.M., Marietti, M., Hardy, T., Henry, L., Eslam, M. et al., 2023. The global epidemiology of NAFLD and NASH in patients with hepatitis B. *Liver International*, 43(7), pp.1395–1404.
- Yu, L., Gao, F., Li, Y., Su, D., Han, L., Li, Y. et al., 2024. Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications. *Biomedicine & Pharmacotherapy*, 175, p.116724.
- Yuen, M.F., Chen, D.S., Dusheiko, G.M., Janssen, H.L., Lau, D.T., Locarnini, S.A., Peters, M.G. and Lai, C.L., 2018. Hepatitis B virus infection. *Nature Reviews Disease Primers*, 4, p.18035. <https://doi.org/10.1038/nrdp.2018.35>
- Zeng, P., Cai, X., Yu, X. and Gong, L., 2023. Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population. *Scientific Reports*, 13, pp.1–8. <https://doi.org/10.1038/s41598-023-47269-4>
- Zhang J, Lin S, Jiang D, Li M, Chen Y, Li J, et al. 2021. Multifaceted Interaction Between Hepatitis B Virus Infection and Lipid Metabolism in Hepatocytes: A Potential Target of Antiviral Therapy for Chronic Hepatitis B. *Front Microbiol.* 12:636897. doi: 10.3389/fmicb.2021.636897.
- Zhang M, Chen S, Wu X, et al. 2023. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection. *J Med Virol.* 95(10):e29156. doi: 10.1002/jmv.29156.
- Zhang RN, Pan Q, Zhang Z, et al. 2015. Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by toll-like receptor 4-mediated innate immune response. *Hepat Mon.* 15(5):e27909.
- Zhang Z, Pan Q, Duan XY, et al. 2012. Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. *J Gastroenterol Hepatol.* 27(12):1858-1864.
- Zhang, H., Zhan, Q., Dong, F., Gao, X., Zeng, F., Yao, J. et al., 2023. Associations of Chinese visceral adiposity index and new-onset stroke in middle-aged and older Chinese adults: an observational study. *Lipids in Health and Disease*, 22(1), p.74.
- Zhang, S., Du, T., Zhang, J., Lu, H., Lin, X., Xie, J., Yang, Y. and Yu, X., 2017. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. *Lipids in Health and Disease*, 16(1), p.15. <https://doi.org/10.1186/s12944-017-0409-6>
- Zhao, K., Zhang, H., Ding, W., Yu, X., Hou, Y., Liu, X. et al., 2025. Adipokines regulate the development and progression of MASLD through organellar oxidative stress. *Hepatology Communications*, 9(2), p.e0639.

- Zheng RD, et al. 2013. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis. *Int J Med Sci.* 10(5):641-646.
- Zheng, Q., Zou, B., Wu, Y., Yeo, Y., Wu, H., Stave, C.D. et al., 2021. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. *Alimentary Pharmacology & Therapeutics*, 54(9), pp.1100–1109. <https://doi.org/10.1111/apt.16595>
- Zhou, T., Ding, X., Chen, L., Huang, Q. and He, L., 2025. Visceral adiposity index as a predictor of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study. *BMC Gastroenterology*, 25(1), p.326. <https://doi.org/10.1186/s12876-025-03957-1>